Navigation Links
Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
Date:6/17/2011

erience.

About the Avanafil Phase 3 ProgramThe avanafil phase 3 program consists of three studies: TA-301 (REVIVE), TA-302 (REVIVE-Diabetes), and TA-303 (REVIVE-RP) and a 52-week, open-label, long-term safety study (TA-314). TA-301, TA-302 and TA-303 were all randomized, double-blind, placebo-controlled phase 3 studies of avanafil in 646, 390, and 298 men respectively with a history of ED for at least six months.  Each of the pivotal trials had a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies were improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF domain score of the International Index of Erectile Function (IIEF). In all three studies, all doses of avanafil tested met the primary endpoints, with successful intercourse achieved by some subjects in 15 minutes or less after administration.  

TA-314 evaluated avanafil for up to 52-weeks in 712 men, 486 with a history of ED and 226 diabetic men with ED across 40 centers throughout the U.S.  Patients completing REVIVE (TA-301) or REVIVE-Diabetes (TA-302) were eligible for rollover into TA-314.  The study met all primary endpoints by demonstrating sustained improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvements in the International Index of Erectile Function (IIEF).  The study also indicated a favorable side effect profile and successful intercourse (as measured by SEP 3) in as little as 15 minutes and beyond six hours after dosing, without any restrictions on food or alcohol intake.

VIVUS held a pre-NDA meeting with the FDA to confirm that the pre-clinical and clinical requirements necessary for the filing of an NDA have been met. In total, the phase 3 avanafil clinical program enrolled approximately 1,350 subjects. VIVUS
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
3. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
6. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
7. KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
8. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
9. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
10. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule ... data on the Australia Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... , Capsule Endoscopes , Capsule ... The report also provides company shares and ...
(Date:7/25/2014)... MISSION, Kan. , July 25, 2014 /PRNewswire-iReach/ ... , and TCGRx, of Powers Lake, ... exclusive partners in a distribution and co-marketing agreement ... to retail pharmacies throughout the United ... of robotics-based pharmacy management and workflow systems to ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: ... Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... acquisition of both cultivation and dispensary medical marijuana licenses in ... the MOU, GBLX will acquire a 20% equity interest in ... GrowBLOX TM growing chambers, as well as all technology ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) announced ... performed by Access collaborators at two,prominent institutes ... the joint,symposium of the American Association for ... European Organization for Research and Treatment,of Cancer ...
... Cells has Potential to Yield High ... and Therapeutic Products, ST. LOUIS and RICHMOND, Calif., Oct. ... Inc.,(Nasdaq: SGMO ) announced today the publication of data ... human stem,cells. This work represents a significant advance in the ...
Cached Medicine Technology:Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 2Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 4Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 5
(Date:7/26/2014)... (PRWEB) July 26, 2014 The European Artificial ... in Europe with analysis and forecast of revenue. The artificial ... $3.5 billion in 2013 to around $5.4 billion by 2018, ... , Browse through the TOC of European artificial lift market ... also provides a glimpse of the segmentation in European Artificial ...
(Date:7/26/2014)... “Today, we introduce our new items of prom ... All these models are offered at discounted prices, and ... says the CEO of the company. DressesOnlineShops.co.uk is one ... outfits. , Ladies have to find a dress solution ... the best choices for many ladies worldwide to buy ...
(Date:7/26/2014)... 2014 “Healthy teeth are important, and having ... whites shining,” says Community Health Center of Snohomish County (CHC) ... They believe that an integration of medical and dental care ... Because of this, they encourage regular cleanings and checkups not ... , “Children and adults will find knowledgeable and ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 Another DePuy Pinnacle ... Orthopedics, Inc., has been filed by Wright & Schulte LLC. ... on behalf of an Erie County, Ohio man who ... left hip and groin since receiving his Pinnacle Hip implant ... man will be forced to undergo a complex and risky ...
(Date:7/26/2014)... 26, 2014 As the category ... true vision of Xoçai is to ... exclusive and healthy chocolate products. One such unique ... cacao, açaí berries and blueberries, an ingredient combination ... blend is utilized in all of Xoçai products ...
Breaking Medicine News(10 mins):Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Artificial Lift Services Market is Expected to Reach $5.4 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4
... Health Solutions, Inc. (NYSE: MHS ) Chairman ... deliver the Keynote Luncheon Address to the American Enterprise ... Care?" on Wednesday, March 18, 2009, at 12:30 p.m. ... federal funding will be directed at expanding the use ...
... Offers Life Saving Tips to Prevent Accidental PoisoningSAN ... poisonings are reported each year to poison control ... California Poison Control System (CPCS) is dedicated to ... 24-hour assistance relating to poisoning. National Poison ...
... Using a novel genetic technology that covers up genetic ... of Health have developed a successful treatment for dogs ... paralyzing, and ultimately fatal, muscle disease. , The technology, ... molecules as molecular "patches." These patches cover up mutant ...
... French-Israeli scientific agreement, known as the European Associated ... Hebrew University of Jerusalem on Wednesday, March 18, ... in Neuroscience. , The new agreement marks ... as the France-Israel International Associated Laboratory Agreement, which ...
... - A researcher has developed probes that can help ... be able to directly attack cancer cells. , Joseph ... biological engineering, developed the nanoscale, multifunctional probes, which have ... cancer cells. , A paper detailing the technology was ...
... INDIANAPOLIS, March 16 More than 35,000 people had ... surgery less than six weeks after diagnosis, according to ... period, conducted by HealthCore, WellPoint,s outcomes research subsidiary.Many people ... out of 10 Americans at some point in their ...
Cached Medicine News:Health News:Media Advisory: Medco CEO David B. Snow Jr. To Address American Enterprise Institute: 'Health IT: Empowering Precision Medicine' 2Health News:Poison Prevention Week March 15 - 22 2Health News:Poison Prevention Week March 15 - 22 3Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 2Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 3Health News:France-Israel scientific cooperation agreement 2Health News:Nanoscopic probes can track down and attack cancer cells 2Health News:Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study 2Health News:Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study 3Health News:Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study 4Health News:Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study 5
Corneal Marking Pen - Sterile. 10 pieces/box...
Replacement PTFE Blocks - 5 centration holes for optimal positioning. 1 piece per box....
... The 4.5/5.0 mm Cannulated Screw ... series of modular systems developed ... screws ranging from 3.5mm to ... and screws, the system was ...
... The 3.5/4.0 mm Cannulated Screw System is ... by DePuy ACE for cannulated screws ranging from ... screw options with necessary instrumentation, the system provides ... the OR staff. The 3.5/4.0 mm system may ...
Medicine Products: